Drug Profile
Research programme: bromodomain containing 4 protein inhibitors - EPIGeNE Therapeutics/Epigenetix
Alternative Names: NEO 1132Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Epigenetix; NEOMED
- Developer EPIGeNE Therapeutics; Epigenetix
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors; P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 20 Oct 2019 Pharmacodynamics data from in vitro studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2019)